Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24
±³À°ÀÏÀÚ : 2024-05-24
±³À°Àå¼Ò : ¼¿ï°¡µçÈ£ÅÚ 2F ±×·£µåº¼·ëȦ
±³À°ÁÖÁ¦ : Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 02-790-2426
À̸ÞÀÏ : ksth@thrombo.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á¹ý, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ±âŸ 10,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 05¿ù 24ÀÏ È¦A 08:50~09:00 °³È¸»ç ()
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 09:00~09:30 Prediction scoring system for TTP: Brief review and introduction of recent study ¹Ú»óÇõ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 09:00~09:30 Cutting edge on the management of acute coronary syndromes ¹ÎÇʱâ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 09:30~10:00 Prediction of thrombosis in myeloproliferative neoplasms À̼ºÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 09:30~10:00 Cutting edge on the management of AF ½ÉÀç¹Î(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 10:00~10:30 Comprehension of EVH and BTH in PNH patients with anti-complement treatment ¾È¼¿¬(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 10:00~10:30 Role of factor XI for thrombosis; A new horizon in anticoagulation therapy ±èº¸Çö(¼øõÇâÀÇ´ë)
ÈÞ½Ä 05¿ù 24ÀÏ 10:30~10:45 coffee break ()
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 10:45~11:15 What strategies would we recommend in patients with bleeding on DOAC treatment? ±è¾ç±â(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 10:45~11:15 Association between peripheral artery disease and AF ÇÑ»óÁø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 11:15~11:45 Anticoagulation therapy in challenging situation ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 11:15~11:45 Coagulation changes in critically ill patients with mechamical circulatory supports À§Áø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 11:45~12:15 New Targets for anticoagulation - beyond DOAC ±è»ó¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 11:45~12:15 Prosthetic mechanical valve thrombosis °¹Î°æ(ÇѸ²ÀÇ´ë)
½Ä»ç 05¿ù 24ÀÏ 12:15~13:15 Lunch ()
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 13:15~13:45 Epidemiology, risk factors (risk assessment), and clinical impact of VTE in acutely ill hospitalized patients ±èÁø¿µ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 13:15~13:45 Strategizing Platelet-Endothelial Interactions: Pioneering Therapeutic Approaches in Hematology Preeti Kumari Chaudhary(ÃæºÏ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 13:45~14:15 Phamarcological and mechanical prophylaxis for VTE in acutely ill hospitalized patients À̵¿Çö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 13:45~14:15 Laboratory diagnosis of von Willebrand disease ¾È¾Æ¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 14:15~14:45 Screening and prophylaxis for asymptomatic DVT in acutely ill patients ÀÌÈÀÇ´ë(¹Ú¼Ò¿µ)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 14:15~14:45 Platelet-type Von Willebrand disease: New Insights into the Molecular Pathophysiology of a Unique Platelet Defect Ãß´ëÇö(¿ï»êÀÇ´ë)
ÈÞ½Ä 05¿ù 24ÀÏ 14:45~15:00 coffee break ()
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 15:00~15:30 Gene therapy in hemophilia A Çѽ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 15:00~15:20 TKI-induced cardiovascular disease in patients with CML ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 15:30~16:00 Assessment of heavy menstrual bleeding À±º¸Çö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 15:20~15:40 Interpretation of cardiac biomarker elevation: Principles and pitfalls ȲÈñÁ¤(°æÈñÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦A 16:00~16:30 Diagnosis & management of DIC È«»ó¹ü(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 15:40~16:00 Management of low thrombotic burden VTE in cancer patients ÀÓÈ£¿µ(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 05¿ù 24ÀÏ È¦B 16:00~16:20 Left Atrial Dysfunction and Cardioembolic Stroke in Patients with Hematologic Disease ¹ÚÇõÁø(Àü³²ÀÇ´ë)
Åä·Ð 05¿ù 24ÀÏ È¦B 16:20~16:30 discussion ±èÇõ,±è°æÇÏ,ÃÖ°¿î(°¡ÃµÀÇ´ë, ¼øõÇâÀÇ´ë, ¿µ³²ÀÇ´ë)
±âŸ 05¿ù 24ÀÏ È¦A 16:30~16:40 Æóȸ½Ä ()
±âŸ 05¿ù 24ÀÏ È¦A 16:40~17:00 ÃÑȸ ()